HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98

Devin Sok; Dennis R Burton

doi:10.1016/j.immuni.2016.10.033

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98

Immunity. 2016 Nov 15;45(5):958-960. doi: 10.1016/j.immuni.2016.10.033.

Authors

Devin Sok¹, Dennis R Burton²

Affiliations

¹ International AIDS Vaccine Initiative, New York, NY 10004, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: devinsok@scripps.edu.
² Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129, USA. Electronic address: burton@scripps.edu.

Abstract

In this issue of Immunity, Huang et al. (2016) describe an exceptionally broad and potent neutralizing antibody to HIV. This antibody, N6, is capable of neutralizing up to 98% of global isolates with a potent median IC₅₀ of 0.04 μg/mL, making it the current "best-in-class" for bNAbs targeting the CD4 binding site.

Publication types

Comment

MeSH terms

Antibodies, Neutralizing / immunology*
HIV Antibodies / chemistry*
HIV Infections / immunology
HIV-1 / immunology
Humans

Substances

Antibodies, Neutralizing
HIV Antibodies

Grants and funding

UM1 AI100663/AI/NIAID NIH HHS/United States